28.11.2023 22:30:06 - dpa-AFX: GNW-Adhoc: Nyxoah Strengthens its Executive Leadership Team
Nyxoah Strengthens its Executive Leadership Team
Francis Kim appointed as Chief Regulatory and Quality Officer
Mont-Saint-Guibert, Belgium - November 28, 2023, 10:30pm CET / 4:30pm ET -
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a
medical technology company focused on the development and commercialization of
innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the
appointment of Francis Kim as Chief Regulatory and Quality Officer. Francis will
be leading Nyxoah's Global Regulatory and Quality departments.
Francis is a highly experienced global regulatory and quality executive in the
healthcare industry, having spent more than 25 years in the medical device and
life sciences sector. Francis has led Regulatory and Quality departments at
Medtronic, Philips, and other companies, including introducing several
innovative products and therapies to the market.
"Nyxoah is entering the most exciting time in the Company's history, with data
from the DREAM U.S. pivotal study in early 2024, followed by submission of the
final module in our modular PMA and FDA approval expected by the end of the
year. I am excited having someone with Francis' regulatory and quality
experience joining Nyxoah at this important time, and I look forward to
continued investments as we prepare to for a U.S. market entrance," commented
Olivier Taelman, Nyxoah Chief Executive Officer.
About Nyxoah
Nyxoah is a medical technology company focused on the development and
commercialization of innovative solutions to treat Obstructive Sleep Apnea
(OSA). Nyxoah's lead solution is the Genio® system, a patient-centered, leadless
and battery-free hypoglossal neurostimulation therapy for OSA, the world's most
common sleep disordered breathing condition that is associated with increased
mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision
that OSA patients should enjoy restful nights and feel enabled to live their
life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system
received its European CE Mark in 2019. Following the positive outcomes of the
BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its
therapeutic indications to Complete Concentric Collapse (CCC) patients,
currently contraindicated in competitors' therapy. Additionally, the Company is
currently conducting the DREAM IDE pivotal study for FDA and U.S.
commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution - CE marked since 2019. Investigational device in the United States.
Limited by U.S. federal law to investigational use in the United States.
Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com (mailto:david.demartino@nyxoah.com)
+1 310 310 1313
Â